https://scholars.lib.ntu.edu.tw/handle/123456789/625234
標題: | Non-hepatic alkaline phosphatase, hs-CRP and progression of vertebral fracture in patients with rheumatoid arthritis: A population-based longitudinal study | 作者: | Yeh, Jih-Chen Wu, Chang-Chin Choy, Cheuk-Sing SHU-WEI CHANG Liou, Jian-Chiun Chen, Kuo-Shu Tung, Tao-Hsin Lin, Wei-Ning Hsieh, Chih-Yu Ho, Chun-Ta TING-MING WANG Chang, Jia-Feng |
關鍵字: | Alkaline phosphatase; C-reactive protein; Rheumatoid arthritis; Vertebral fractures | 公開日期: | 13-十一月-2018 | 卷: | 7 | 期: | 11 | 來源出版物: | Journal of Clinical Medicine | 摘要: | Background: Interactions and early warning effects of non-hepatic alkaline phosphatase (NHALP) and high-sensitivity C-reactive protein (hs-CRP) on the progression of vertebral fractures (VFs) in patients with rheumatoid arthritis (RA) remain unclear. We aim to explore whether serum concentrations of NHALP and hs-CRP could serve as a promising dual biomarker for prognostic assessment of VF progression. Methods: Unadjusted and adjusted hazard ratios (aHRs) of VF progression were calculated for different categories of serum NHALP and hs-CRP using the Cox regression model in RA patients. The modification effect between serum NHALP and hs-CRP on VF progression was determined using an interaction product term. Results: During 4489 person-years of follow-up, higher NHALP (>125 U/L) and hs-CRP (>3.0 mg/L) were robustly associated with incremental risks of VF progression in RA patients (aHR: 2.2 (95% confidence intervals (CIs): 1.2–3.9) and 2.0 (95% CI: 1.3–3.3) compared to the lowest HR category, respectively). The interaction between NHALP and hs-CRP on VF progression was statistically significant (p < 0.05). In the stratified analysis, patients with combined highest NHALP and hs-CRP had the greatest risk of VF progression (aHR: 4.9 (95% CI: 2.5–9.6)) compared to the lowest HR group (NHALP < 90 U/L and hs-CRP < 1 mg/L). Conclusions: In light of underdiagnoses of VFs and misleading diagnosis by single test, NHALP and hs-CRP could serve as compensatory biomarkers to predict subclinical VF progression in RA patients. © 2018 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080123050&doi=10.3390%2fjcm7110439&partnerID=40&md5=ba94aac36030c78939cc51865849b4d1 https://scholars.lib.ntu.edu.tw/handle/123456789/625234 |
ISSN: | 20770383 | DOI: | 10.3390/jcm7110439 | SDG/關鍵字: | alanine aminotransferase; albumin; alkaline phosphatase; C reactive protein; creatinine; hemoglobin; hemoglobin A1c; potassium; rheumatoid factor; sodium; triacylglycerol; uric acid; adult; Article; cohort analysis; computer assisted tomography; diabetes mellitus; disease exacerbation; erythrocyte sedimentation rate; estimated glomerular filtration rate; female; follow up; glucose blood level; human; hyperlipidemia; hypertension; leukocyte count; longitudinal study; major clinical study; male; middle aged; osteoporosis; radiography; retrospective study; rheumatoid arthritis; smoking; spine fracture; total cholesterol level; urea nitrogen blood level |
顯示於: | 土木工程學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。